Immuno-oncology Clinical Trials Market To Reach USD 14.7 Billion By 2032 – DataHorizzon Research

Intense Research and Development for Immuno-oncology to Offer Therapeutic Breakthroughs.

Fort Collins, Colorado, April 04, 2024 (GLOBE NEWSWIRE) — The Immuno-oncology Clinical Trials Market size was valued at USD 5.4 Billion in 2023 and is expected to reach a market size of USD 14.7 Billion by 2032 at a CAGR of 11.8%.

The rising global prevalence of cancer is a primary driver of immuno-oncology clinical trials. As cancer rates rise, there is a larger need for novel and effective treatment options, which increases the demand for clinical trials to evaluate new immuno-oncology drugs. Moreover, novel immunotherapies have emerged due to complex interactions between the immune system and cancer cells.

Pharmaceutical and biotechnology companies invest heavily in R&D to discover and develop new immunotherapeutic medications, including immune checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, and cytokine therapies. The growing number of immunotherapy drugs has prompted a rise in clinical studies in immuno-oncology. The immuno-oncology trials market has experienced positive growth in the past few years owing to a significant increase in clinical trials conducted worldwide. The investments by pharmaceutical businesses and institutions for immuno-oncology research and development further fuels innovation. In addition, the market is undergoing therapeutic breakthroughs that offer hope to patients battling several types of cancer.

Request Sample Report: 

https://bit.ly/3VK4EFK

Segmentation Overview:

The global immuno-oncology clinical trial market has been segmented into therapy type, cancer type, trial phase, and region. Based on therapy type, the market is segmented into checkpoint inhibitors, CAR-T cell therapy, cytokine therapy, adoptive cell transfer therapy, cancer vaccines, and others. Checkpoint Inhibitors are expected to dominate the market growth in the forecast period because checkpoint inhibitors rank among the most extensively researched immunotherapy treatments in clinical trials.

Buy This Research Report: 

https://bit.ly/3TNtXUK

Global Immuno-oncology Clinical Trials Market Report Highlights:

  • The global immuno-oncology clinical trial market growth is anticipated at a CAGR of 11.8% by 2032.
  • The rising global prevalence of cancer is a primary driver of immuno-oncology clinical trials. As cancer rates rise, there is a larger need for novel and effective treatment options, which increases the demand for clinical trials to evaluate new immuno-oncology drugs. The National Institutes of Health estimates that around two million people in the United States were diagnosed with cancer in 2023.
  • North America will dominate market growth as it generates a significant revenue share due to its well-developed healthcare infrastructure, solid regulatory environment, notable academic and research institutions, and a large number of clinical trial sites and investigators.
  • Some prominent players in the global immuno-oncology clinical trials market report include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann La Roche Ltd. (Genentech), AstraZeneca, Novartis AG, Pfizer Inc., Johnson & Johnson (Janssen), AbbVie Inc., Amgen plc., GSK plc., Moderna, Inc., Regeneron Pharmaceuticals, Incyte Corporation, Eli Lilly and Company. 

Looking Exclusively For Region/Country Specific Report?

https://bit.ly/49hPHxW

OR

Ask For Discount 

https://bit.ly/49pfLYb

Immuno-oncology Clinical Trial Market Segmentation:

By Therapy Type: Checkpoint Inhibitors (e.g., PD-1, PD-L1, CTLA-4 inhibitors), CAR-T Cell Therapy, Cytokine Therapy, Adoptive Cell Transfer Therapy, Cancer Vaccines, Others

By Cancer Type: Melanoma, Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Lymphoma, Prostate Cancer, Others

By Trial Phase: Phase I, Phase II, Phase III, Phase IV

By Region: North America, Latin America, Europe, Asia Pacific, the Middle East and Africa.

 

About DataHorizzon Research:

DataHorizzon is a market research and advisory company that assists organizations across the globe in formulating growth strategies for changing business dynamics. Its offerings include consulting services across enterprises and business insights to make actionable decisions. DHR’s comprehensive research methodology for predicting long-term and sustainable trends in the market facilitates complex decisions for organizations.

Contact:

Mail: sales@datahorizzonresearch.com

Ph: +1-970-672-0390

Website: https://datahorizzonresearch.com/

Follow Us: LinkedIn 

 

Recent Publications

Healthcare Predictive Analytics Market Size

Implantable Medical Device Market Size

Over the Counter (OTC) Drugs Market Size

Drug Discovery Market Size

Targeted DNA RNA Sequencing Market Size

CONTACT: Mail: sales@datahorizzonresearch.com Ph: +1-970-672-0390 Website: https://www.datahorizzonresearch.com 

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Privacy & Cookies Policy